Should Celgene Investors Take Bristol's Money and Run?

In 2018, Bristol-Myers Squibb (NYSE:BMY) relied on just two products to drive growth, and the pharma giant's late-stage development pipeline looks like Old Mother Hubbard's cupboards. Investors know that Bristol-Myers needs to do something to continue pushing the needle forward, but a $74 billion offer for Celgene (NASDAQ:CELG) might not have been what they had in mind.